Any current/future new fundraising through debt or equity?

The transcript does not mention any current or planned fundraising through debt or equity. Focus is on ongoing CAPEX at Sarigam facility with expected spend of around Rs.130-150 crores in FY23 and Rs.100-125 crores in FY24. Management is confident of growth and operational performance, but no discussion on raising funds externally. No indications of equity issuance or new debt plans during the call. Emphasis remains on internal funding through operational cash flows and CAPEX for expansion.

Any current/future capex/capital investment/strategic investment?

FY23 CAPEX guidance is around Rs. 130 to 150 crores. FY24 CAPEX guidance is around Rs. 100 to 125 crores. Total CAPEX spent on Sarigam facility till date is around Rs. 35 to 40 crores. Sarigam facility Phase 1 production expected to commence by Q4 FY23. Sarigam is a technical plant with expected turnover ratio of 3.5 to 4 times capacity. The Sarigam facility will enable launch of new products and expand product portfolio. The company is actively investing in R&D with about 15 products in development; 5 shortlisted for registration, 2 planned for launch next year. Investments are aimed at incre

Future growth expectations in sales/revenue/volumes?

Management expects 16% to 18% revenue growth for FY23, driven approximately equally by volume and price increases. Volume growth is guided around 8% to 10%. Price hikes around 3% have been implemented to offset raw material cost inflation and maintain EBITDA margins. Post Q1 challenges due to COVID and China lockdowns are easing, with expectations of recovery and robust growth in subsequent quarters. New product launches (two planned in FY23) and increased registrations aim to expand product portfolio and customer base. Ramp-up in exports to developed markets like US and Europe is expected fro

Future growth expectations in earnings/operating earnings/profits/EPS?

Management revised FY23 guidance to 15%-17% sales growth and 16%-18% EBITDA margins, down from earlier 18%-20% guidance due to Q1 challenges. They remain confident in long-term EBITDA margin guidance of 18%-20%. Volume growth expected at 8%-10%, with price hikes (~3%) contributing to revenue growth. Recovery expected in exports, particularly China, post lockdowns, leading to normalized growth in coming quarters. New product registrations and launches (2 products planned in FY23) to drive growth and margin improvement. Ongoing Sarigam facility CAPEX to start contributing from Q4 FY23,

Current/ Expected Orderbook/ Pending Orders?

After supplying the first consignment of insecticide to the US, Heranba made two supplies last year. For the current year, they have received a tentative partial order for trial shipment. Successful trial trials to lead to larger confirmed orders. The previous two consignments included a trial order followed by a repeat order. By Q3 end, the company expects clarity on the status of ongoing trial orders. Several customer visits and audits are planned or underway, facilitating order ramp-up. The Sarigam facility is gearing up with registrations and trials, expected to aid scaling volumes from ne

IN US

Sale is live|00:00:00left today

Heranba Industries LtdQ2 FY22Fertilizers & Agrochemicals

Heranba Industries Ltd Q2 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹187Market Cap: ₹818 CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Management expects 16% to 18% revenue growth for FY23, driven approximately equally by volume and price increases.
→Volume growth is guided around 8% to 10%.
→Price hikes around 3% have been implemented to offset raw material cost inflation and maintain EBITDA margins.
→Post Q1 challenges due to COVID and China lockdowns are easing, with expectations of recovery and robust growth in subsequent quarters.
→New product launches (two planned in FY23) and increased registrations aim to expand product portfolio and customer base.
→Ramp-up in exports to developed markets like US and Europe is expected from FY24 onwards after facility audits and regulatory clearances.
→Sarigam facility commissioning by Q4 FY23 will contribute new molecules and production capacity, supporting growth.
→Long-term EBITDA margin targets remain 18-20%, indicating confidence in sustainable volume and margin growth.

Margin guidance

Category 3

→Management revised FY23 guidance to 15%-17% sales growth and 16%-18% EBITDA margins, down from earlier 18%-20% guidance due to Q1 challenges.
→They remain confident in long-term EBITDA margin guidance of 18%-20%.
→Volume growth expected at 8%-10%, with price hikes (~3%) contributing to revenue growth.
→Recovery expected in exports, particularly China, post lockdowns, leading to normalized growth in coming quarters.
→New product registrations and launches (2 products planned in FY23) to drive growth and margin improvement.
→Ongoing Sarigam facility CAPEX to start contributing from Q4 FY23, expected to support revenue growth with turnover ratio of 3.5-4x.
→Management optimistic about overcoming short-term headwinds and expects robust earnings growth beyond FY23.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→The transcript does not mention any current or planned fundraising through debt or equity.
→Focus is on ongoing CAPEX at Sarigam facility with expected spend of around Rs.130-150 crores in FY23 and Rs.100-125 crores in FY24.
→Management is confident of growth and operational performance, but no discussion on raising funds externally.
→No indications of equity issuance or new debt plans during the call.
→Emphasis remains on internal funding through operational cash flows and CAPEX for expansion.

Order book

→After supplying the first consignment of insecticide to the US, Heranba made two supplies last year.
→For the current year, they have received a tentative partial order for trial shipment.
→Successful trial trials to lead to larger confirmed orders.
→The previous two consignments included a trial order followed by a repeat order.
→By Q3 end, the company expects clarity on the status of ongoing trial orders.
→Several customer visits and audits are planned or underway, facilitating order ramp-up.
→The Sarigam facility is gearing up with registrations and trials, expected to aid scaling volumes from next financial year.
→Some soft visibility exists for new molecules, though no confirmed orders can be disclosed presently.

Capex plans

Yes

→FY23 CAPEX guidance is around Rs. 130 to 150 crores.
→FY24 CAPEX guidance is around Rs. 100 to 125 crores.
→Total CAPEX spent on Sarigam facility till date is around Rs. 35 to 40 crores.
→Sarigam facility Phase 1 production expected to commence by Q4 FY23.
→Sarigam is a technical plant with expected turnover ratio of 3.5 to 4 times capacity.
→The Sarigam facility will enable launch of new products and expand product portfolio.
→The company is actively investing in R&D with about 15 products in development; 5 shortlisted for registration, 2 planned for launch next year.
→Investments are aimed at increasing global registrations and entering new geographies like US and Europe.
→The company remains confident of long-term growth and margin improvement backed by these investments.

How does Heranba Industries Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

1Heranba Industries Ltd

Rev 3Mar 3

See full Fertilizers & Agrochemicals sector rankings

Want more stocks like Heranba Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio